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large (13-18) and extremely large effects (19-30). Severity of disease was 
measured using the Nottingham Eczema Severity scores (NESS). RESULTS: The 
average QOL scores reported were 15.0±6.69 among infants (IDQOL); 16.4±7.25 
among children (CDLQI), and 15.5±7.59 among families (DFI). The mean IDQOL, 
CDLQI and DFI scores were higher in patients with severe AD (16.7±6.66, 
18.4±6.99, and 17.5±7.53, respectively) than among those with moderate AD 
(13.9±6.49, 15.2±7.14, and 14.2±7.35, respectively). A large proportion of 
respondents experienced extremely large effect of QOL scores (scoring 19 to 30), 
including 35.6% of infants, 44.0% of children and 39.1% of families. There were 
also large differences between the reported QOL from different countries. 
CONCLUSIONS: The study found that moderate to severe AD affected the QOL of 




IMPACT OF SEVERE AND VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE (COPD) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND WORK 
PRODUCTIVITY: RESULTS OF A NATIONALLY REPRESENTATIVE PATIENT 
SURVEY AND CHART REVIEW OF RECENTLY EXACERBATING PATIENTS  
Solem CT1, Sun SX2, Sudharshan L1, Macahilig C3, Katyal M3, Gao X1 
1Pharmerit International, Bethesda, MD, USA, 2Forest Research Institute, Jersey City, NJ, USA, 
3Medical Data Analytics, Parsippany, NJ, USA  
BACKGROUND: Understanding COPD exacerbation-associated burden, 
particularly in severe (SEV) and very severe (VSEV) patients, can help improve 
medication management. OBJECTIVES: To describe exacerbation frequency, 
treatment, work productivity, and health-related quality of life (HRQoL) for 
patients with SEV/VSEV COPD who recently experienced a moderate (MOD)/SEV 
exacerbation. METHODS: A nationally representative sample of SEV/VSEV COPD 
patients who had experienced a MOD/SEV exacerbation within the past 3 
months was physician recruited. Medical charts were evaluated for patient 
demographic/clinical data, including exacerbation frequency in the previous 12 
months, work productivity and impairment (WPAI), and HRQoL (St. George’s 
Respiratory Questionnaire for COPD, SGRQ-C). RESULTS: This study included 314 
patients (190 SEV/124 VSEV). VSEV (vs. SEV) patients were more likely to be 
Caucasian (93.5% versus 82.1%, P=0.004) and had SEV last exacerbation (44.3% vs. 
29.5%, P=0.016). These 314 patients experienced 829 exacerbations in the 
previous 12 months, of which 556 were MOD (17.2% treated with antibiotics only; 
70.7% with steroids and antibiotics; 12.1% with steroids only), and 273 were SEV 
(19.6% treated in the ER; 53.7% hospitalized with an ER visit; 26.7% hospitalized 
without ER visit). 15.9% of patients (SEV 19.5%/VSEV 10.5%, P=0.033) were 
employed but reported a high percentage of overall work impairment 
(42.4%±31.1%) due to absenteeism/presenteeism. Activity impairment was 
58.7%±28.0% across all patients. SGRQ-C scores (0-100=best-worst health) were: 
Total 64.7±20.4, Symptoms 70.6±19.0, Activities 78.0±21.9, and Impacts 54.7±24.8, 
with total scores being significantly worse for VSEV (vs. SEV COPD; 70.1±21.3 vs. 
61.1±19.0; P<0.001) and SEV last exacerbation (vs. MOD; 70.3±19.9 vs. 61.7±20.1; 
P<0.001). CONCLUSIONS: MOD/SEV exacerbations in SEV/VSEV COPD patients 
impaired patients’ work productivity and were associated with poor HRQoL. 
Since patients with a recent MOD/SEV exacerbation were highly likely to have 
experienced mild/MOD/SEV exacerbations in the previous year, interventions to 
further reduce exacerbations will likely have a strong impact on patient HRQoL.  
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PRS49  
MULTICOMPONENT HOME-BASED ENVIRONMENTAL INTERVENTIONS ARE 
EFFECTIVE IN REDUCING MORBIDITY OF CHILDREN WITH ASTHMA FROM LOW 
INCOME FAMILIES  
Nurmagambetov T1, Uzoebo V2, Hayes R2 
1Centers for Disease Control and Prevention, Atlanta, GA, USA, 2NYC Department of Health and 
Human Hygiene, New York, NY, USA  
OBJECTIVES: To analyze the effectiveness of a multicomponent home-based 
environmental asthma intervention targeting children from low income families 
in East Harlem, New York City. METHODS: Three hundred eighty children aged 
17 years or younger with asthma participated in the study. These children and 
their families were assessed for baseline characteristics including asthma 
symptoms and health care utilization experienced by a child; presence of home 
environmental triggers; and parents’ knowledge and skills in managing the 
child’s asthma. Based on baseline characteristics, families that received 
environmental intervention (n=200) were compared with those that did not 
(n=18). The main asthma outcomes were rates of emergency department visits 
(edv), hospitalizations (hsp), asthma symptom days (asd), school days missed 
(sdm), and work days missed (wdm) due to asthma. Observable variables 
included age, gender, race, and baseline rates of edv, hsp, asd, sdm, and wdm. 
The effect of the intervention was measured as the difference in the main 
asthma outcomes at the baseline and at post-intervention assessment. To 
reduce the influence of confounding factors we applied propensity score method 
to estimate effect of the intervention on the main asthma outcomes. RESULTS: 
Baseline main asthma outcomes were: 2.56 (intervention group) and 2.64 (control 
group) for edv, 0.44 and 0.62 for hsp, 7.35 and 5.86 for asd, 5.38 and 6.96 for sdm, 
and 6.95 and 3.57 for wdm. The average treatment effect of the intervention was 
2.13 for edv, 0.92 for hsp, 2.67 for asd, 1.95 for sdm, and 1.89 for wdm. All 
estimates, except hospitalizations, were significant. The unmatched outcomes 
for the same outcomes were 3.36, -0.17, 3.80, 1.66, and 1.48 respectively. 
CONCLUSIONS: The results of the study suggest that low-income families can 
benefit from the intervention by reducing emergency department visits, asthma 
symptom days, and missed school and work days.  
PRS50  
EVALUATION OF ASTHMA-RELATED PHARMACY QUALITY ALLIANCE (PQA) 
MEASURES IN THE MISSISSIPPI MEDICAID POPULATION  
Datar M1, Null KD1, Hardwick SP2, Clark JP2 
1University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS, 
USA  
OBJECTIVES: The National Quality Forum (NQF) has endorsed measures from the 
Pharmacy Quality Alliance (PQA) for suboptimal asthma control (SAC) and 
absence of controller therapy (ACT) to measure the quality of care among 
asthma beneficiaries. The purpose of this study was to evaluate a baseline for 
the Mississippi Division of Medicaid using the PQA measures. METHODS: A 
retrospective cross-sectional analysis of 2008-2012 Mississippi Medicaid claims 
was undertaken. Asthma beneficiaries aged 5 - 50 years as of the last day of each 
measurement year were identified. The inclusion and exclusion criteria were 
applied according to the PQA measure specifications, with an expanded age 
inclusion to account for Medicaid’s pediatric population. Beneficiaries with at 
least 3 canisters of short-acting beta agonists within 90 days were identified as 
those with SAC. Of SAC beneficiaries, those who did not receive controller 
therapy including inhaled steroids, long-acting beta agonists, and leukotriene 
inhibitors in the same 90 day period were defined as those with ACT. Costs were 
compared between ACT and non-ACT beneficiaries for each measurement year. 
RESULTS: A total of 62,557 beneficiaries were identified from 2008 to 2012. The 
percentage of asthma beneficiaries having SAC along with ACT decreased from 
8.08% (2008) to 5.15% (2012). Beneficiaries with ACT (compared to non-ACT 
beneficiaries) had significantly higher asthma-related total costs [$1,516.98 vs. 
$593.66 (2008); $1,571.98 versus $648.78 (2009); $1,586.06 versus $664.36 (2010); 
$1,748.73 versus $722.36 (2011); $1,750.64 versus $709.63 (2012)]. Cost differences 
between the two groups for all the years was significant (p<0.01). CONCLUSIONS: 
This study of an expanded SAC/ACT measure in a Medicaid population found 
that the proportion of ACT beneficiaries has consistently decreased since 2008; 
providing a baseline measure for future interventions. Since beneficiaries with 
ACT have higher costs than non-ACT beneficiaries, further decline in the 
numbers for this population is needed in the coming years.  
 
PRS51  
SMOKING IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS: 
SOCIO-DEMOGRAPHIC FACTORS ASSOCIATED WITH SMOKING CESSATION  
Shah S1, Gangan N1, Bechtol R2, Vaidya V2 
1The University of Toledo, Toledo, OH, USA, 2The University of Toledo, College of Pharmacy and 
Pharmaceutical Sciences, Toledo, OH, USA  
OBJECTIVES: Smoking is one of the major risk factors in chronic obstructive 
pulmonary disease (COPD) patients, with 90% of deaths from COPD being 
attributable to smoking. According to the Centers for Disease Control and 
Prevention (CDC), smoking cessation reduces the risk of developing COPD. Still, 
little is known about the use of smoking cessation agents and the factors that 
affect their use among patients. The purpose of the study is to identify the socio-
demographic factors that affect the use of these agents among COPD patients. 
METHODS: A retrospective study was done to identify smokers having COPD 
(ICD9:490-496) and those who use smoking cessation agents from 2006-2010 
using Medical Expenditure Panel Survey (MEPS) data. A multiple logistic 
regression model was built to identify significant socio- demographic predictors 
associated with the use of smoking cessation agents. RESULTS: Out of 2218 
smokers with COPD, 176 reported use of smoking cessation agents during the 5 
year period. Logistic regression showed African Americans were less likely to use 
smoking cessation agents than Caucasians (OR=0.379, 95% CI 0.208-0.688), 
patients having public insurance were more likely to report use of these agents 
than other insurances (OR=2.619, 95% CI 1.265-5.422), and patients with higher 
educational levels (OR=1.127, 95% CI 1.043-1.217) were more likely to use these 
agents. CONCLUSIONS: Results showed that a large number of patients 
continued to smoke even after the diagnosis of COPD whereas; only 176 patients 
(8%) used smoking cessation agents. Race, educational level, and insurance 
status were significant predictors of smoking cessation agents’ use. Further 
research needs to be done to evaluate reasons for minimal use of these agents in 
COPD patients. Results showed inconsistent use of these agents among different 
population groups; hence there is a requirement for need based smoking 
cessation programs.  
 
PRS52  
DEMOGRAPHIC CHARACTERISTICS OF ASTHMA SUBJECTS THAT STEP-DOWN 
FROM FLUTICASONE PROPIONATE-SALMETEROL COMBINATION  
THERAPY  
NAG A1, Stanford RH2, Shah M3, D'Souza AO4, Dhamane A5 
1GlaxoSmithKline, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Research Triangle Pk, 
NC, USA, 3Xcenda, LLC, Palm Harbor, FL, USA, 4Xcenda, Cincinnati, OH, USA, 5Xcenda, LLC, 
Suite 500, FL, USA  
OBJECTIVES: To compare baseline demographics of long-acting beta-agonist 
(LABA) step down in asthma patients taking fluticasone propionate-salmeterol 
via Diskus (FSC). METHODS: A retrospective observational study using pharmacy 
and medical claims data (Market Scan Commercial Database, January 1, 2006 to 
December 31, 2010). Subjects were included if they had : 1) ≥ 2 FSC prescription 
claims prior to the index (step-down) date; 2) ≥ 1 asthma claim [ICD-9-CM] codes 
493.xx); 3) 12-64 years of age; and 4) continuously eligible for 12 months pre and 
post index. Subjects were excluded if they had: 1) COPD diagnosis (ICD-9 codes 
491.xx, 492, xx, 496.xx), or 2) ≥ 1 prescription claim for anti-cholinergics or 3) 
receipt of higher dose FSC or another asthma controller other than FSC or ICS 
after the index. Step-down was defined as reduction in dose of FSC (lower dose 
FSC) or moving to ICS only without the LABA (ICS monotherapy). These two 
cohorts were matched 1:3 with subjects that remained on the starting FSC dose 
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(same dose FSC). Patient demographics included comorbidity, albuterol use, 
asthma-related health care utilization, number of controllers, number oral 
corticosteroids, number of physician visits, specialist visits, season, time to step-
down and FSC fill rate. Multivariate analysis was performed to determine the 
characteristics related to each step-down. RESULTS: Presence of a specialist visit 
[adjusted Odds Ratio (OR) 1.92, 95% CI 1.77-2.52 and OR 1.47, 95% CI 1.31-1.85] and 
more physician visits (OR=1.16, 95% CI: 1.11-1.28, and OR, 1.17 95% CI 1.11-1.28) 
prior to step-down were significantly associated with step-down of therapy for 
both low dose FSC (n=1,459), and ICS monotherapy (n=1,775) respectively. 
CONCLUSIONS: Subjects with close assessment of asthma disease and specialist 
care may be more likely to step-down from FSC therapy.  
 
PRS53  
UTILIZATION PATTERN OF RESPIRATORY MEDICATIONS AMONG CHRONIC 
OBSTRCTIVE PULMONARY DISEASE PATIENTS IN TAIWAN  
Lin HW1, Yu IW2, Cheng WE2 
1China Medical University, Taichung, Taiwan, 2China Medical University Hospital, Taichung, 
Taiwan  
OBJECTIVES: Incidence of chronic obstructive pulmonary disease (COPD) has 
increased globally. The respiratory medications were the main treatment 
strategies to control for COPD disease progression. The purpose of the current 
study was to explore the utilization pattern of respiratory medications among 
COPD patients in Taiwan. METHODS: A retrospective observational study was 
conducted by using 2000 and 2005 Longitudinal Health Insurance Databases (two 
million random samples). A cohort of national health insurance beneficiaries 
with any newly diagnosis for COPD (International Classification of Diseases, Ninth 
Revision[ICD-9] codes=491.x, 492.x, 496) in 2006 and aged greater than 40-year-old 
was identified. These COPD patients were assessed and followed for one-year 
from the date of their first prescription of any inhaled COPD medications (index 
date) and their persistence of each class of COPD medications was evaluated. 
RESULTS: A cohort of 7838 new COPD cases was identified in 2006. They were 
about 68.9±12.6 years old and male was predominant (67%). Of all, 95% were 
coded with 496. However, only 579(6.9%) were ever prescribed with inhaled COPD 
medications in 2006. The days to the first prescription of inhaled COPD 
medications after diagnosis were 26 days in average, and up to 336 days. Only 
5.5% to 19% of patients continued on the index drug for more than 6 months, 
which decreased to 1 to 5% at 12 months. The long-acting muscarinic antagonist 
(LAMA) showed the highest persistence among the other medications, whereas 
inhaled corticosteroid (ICS) had the lowest. CONCLUSIONS: Respiratory 
medications were obviously under-utilized in Taiwanese patients with COPD. 
Further study is needed to explore the consequence of such phenomenon and its 
potential resolutions.  
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PRESCRIBING LONG-ACTING BETA-AGONISTS AS MONOTHERAPY TO ADULTS 
WITH CONTROLLED AND UNCONTROLLED ASTHMA  
Ali AK1, Hartzema AG2 
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of Florida, Gainesville, FL, USA  
OBJECTIVES: To describe demographic and health care utilization characteristics 
of adults with asthma who initiated inhaled long-acting beta-agonist (LABA) 
bronchodilators as monotherapy. METHODS: A cohort of asthmatic adults with 
controlled and uncontrolled asthma in the General Practice Research Database 
was retrospectively followed to compare the propensity of initiating inhaled 
LABA monotherapy versus any other inhaled controller medication_inhaled 
corticosteroids (ICS) monotherapy or ICS/LABA combination therapy. Patients 
with controlled asthma are defined as not having >2 asthma drug classes or any 
short-acting beta-agonists (SABA) prescribed at the LABA prescribing date; and 
not having any of the following during 12 months before LABA prescribing date: 
prescription for oral corticosteroids, >6 prescriptions for SABA, or attending 
emergency departments or hospitalization for asthma. RESULTS: Among  
the 51,103 patients aged 13-65 who met the inclusion criteria, 60% were 
uncontrolled asthmatics and 40% had controlled asthma. the majority of 
patients in both groups were nonsmoking obese females who visited general 
practices in England. Patients with controlled asthma were more likely to receive 
LABA monotherapy than patients with uncontrolled asthma (OR=2.22, 
95%CI=1.90-2.59). Asthmatics who were prescribed leukotriene receptor 
antagonists (LTRA) were at risk of receiving add-on LABA (OR=7.90, 95%CI=4.27-
13.53). General practices in England were less likely to prescribe LABA 
monotherapy than practices in Scotland, Wales, or Northern Ireland. 
Consultations ≤10 minutes were associated with 38% higher likelihood of 
prescribing LABA monotherapy inhalers than visits with longer duration. 
CONCLUSIONS: Adults with controlled asthma who are ICS-naïve are more likely 
to initiate LABA monotherapy than patients with uncontrolled asthma; however, 
LABA is prescribed as an add-on therapy to anti-inflammatory LTRA in 
controlled asthmatics.  
 
PRS55  
RACIAL AND ETHNIC DISPARITY IN SMOKING CESSATION MEDICATION USE 
AMONG ADULT SMOKERS IN THE UNITED STATES  
Wang X1, Abughosh S2 
1Universtiy of Houston, Houston, TX, USA, 2University of Houston, Houston, TX, USA  
OBJECTIVES: To examine racial/ethnic disparity in smoking cessation 
medication use among adult smokers in the United States. METHODS: A 
retrospective cross-sectional study was conducted using the Medical 
Expenditure Panel Survey (MEPS) data (2009). The study included adults aged ≥ 18 
years who self-reported currently using tobacco. The outcome variable was 
receiving smoking cessation medication use versus not. Andersen's Behavioral 
Model of Health Services Utilization was used as the conceptual framework. The 
independent variables were categorized into predisposing, enabling, and need 
characteristics, including age, gender, race, marital status, education, insurance 
status, family income, region, urban residence, usual source of health care, 
general health status, comorbidity, obesity, activities of daily living. Descriptive 
statistics and chi-square tests were used to examine group differences. 
Multivariate logistic regression analysis was performed to investigate 
racial/ethnic disparity in smoking cessation medication use. RESULTS: Total 
sample was 39,900,131and mostly comprised of Non-Hispanic Whites (73.38%), 
followed by Non-Hispanic Black (12.20%), Hispanics (9.53%), and others (4.88%). 
Race was a significant predictor of smoking cessation medication use. The 
findings indicated that Non-Hispanic Blacks were less likely to use smoking 
cessation medication compared to Non-Hispanic Whites (odds ratio [OR]: 0.39, 
95% confidence interval [CI]: 0.19-0.80). Smokers who live in South were less 
likely to use smoking cessation medication compared with those who live in 
Northeast (OR: 0.43, 95% CI: 0.20-0.93). Obese people were more likely to use 
smoking cessation medication compared to non-obese smokers (OR: 2.68, 95% CI: 
1.69-4.27). Additionally, urban residence was a significant predictor of smoking 
cessation medication use (OR: 2.26, 95% CI: 1.17-4.39). CONCLUSIONS: While 
smoking cessation remains highly recommended for all smokers, Black smokers 
are less likely to use smoking cessation medications compared to White. Further 
research is needed to understand the reasons for this disparity and find ways to 
eliminate it.  
 
PRS56  
ASSESSMENT OF PHYSICIANS' KNOWLEDGE AND PERCEPTIONS TOWARDS 
MEDICINE QUALITY AND PRICES IN KABUL, AFGHANISTAN  
Bashaar M, Hassali MA 
Universiti Sains Malaysia, Penang, Malaysia  
OBJECTIVES: The current study is aimed to assess the knowledge and 
perceptions of physicians towards medicine quality and prices in Kabul City. 
METHODS: In this cross-sectional descriptive survey, a total of 400 physicians 
were approached to be part of the survey and 347 consented to participate 
(response rate of 86.7%). RESULTS: In the survey, 36.6% of physicians felt that the 
quality of imported medicine is good, and 50.8% often felt that medicines given 
by public hospitals are of high quality. However 40.6% disagreed that the Afghan 
Drug Regulatory Authority controls quality of medicine registered in the country. 
Overall, 85.6% of respondents felt that the government should adopt health 
policies to control the medicine prices and expenditures, and 76.3% reported that 
higher medicine costs negatively impacts patient outcomes. Only 45% reported 
that doctors have poor understandings on medicine prices, and 84.5% reported 
that the medicine prices both in the government and private should be made 
public. Among the respondents, 26.3% felt that medicine prices are affordable to 
their patients. A high proportion of the respondents (85.2%) agreed that 
prescription medicine prices must be regulated by the government since 70.3% of 
physicians reported that medicine prices are high in private hospitals. About 
60.5% of the physicians felt that medicine prices influence their prescribing 
decision, and 65.8% agreed that the patient’s income influences their prescribing 
decisions. CONCLUSIONS: Results suggest that physicians must be cost-
conscious and alert in their prescriptions and do not undermine the cost of 
medication. As a conclusion, the Afghan Drug Regulatory Authority should 
control the medicine prices and quality on a regular basis in the market, which 
will act as leverage for sustainable and effective treatment and access to 
essential medicines. Further, the study suggests that there is substantial room 
for improvement in the knowledge of physicians about medicine quality and 
prescription cost.  
 
PRS57  
COMPARISON OF DIAGNOSIS BASED COMORBIDITY INDICES TO PREDICT HIGH 
COST COPD PATIENTS PROSPECTIVELY  
Mhatre SK, Aparasu RR, Johnson ML 
University of Houston, Houston, TX, USA  
OBJECTIVES: High health care costs are incurred by Chronic Obstructive 
Pulmonary Disease (COPD) patients. Identifying high cost patients prospectively 
benefits health care providers and insurance companies. The purpose of  
the current study was to compare the performance of generic and COPD  
specific diagnosis based comorbidity measures in predicting high medical 
expenditures in COPD patients. METHODS: A longitudinal study was conducted 
using nationally representative data from the Medical Expenditure Panel Survey. 
Prediction models were developed using cohorts initiated in 2008-2009  
and validated using cohorts initiated in 2006-2007. Logistic regression was used 
to predict being in the upper expenditure decile in year 2, using data from year 1. 
Three comorbidity measures were compared: D’Hoore Charlson comorbidity 
index, Elixhauser comorbidity index and COPD specific comorbidity Test  
(COTE). Models were evaluated using c-statistics, Hosmer-Lemeshow statistic, 
correlation coefficient and positive prediction value. RESULTS: Comorbidity 
indices improved prediction of high cost COPD patients beyond age and  
gender, with the Elixhauser index providing the best prediction (c-statistic: 0.82), 
followed by COTE (c-statistic: 0.74). The Hosmer-Lemeshow test for both was  
also non-significant, indicating high accuracy. The COTE index had the  
best external validation properties (c-statistics: 0.66, Hosmer-Lemeshow: 7.4), 
followed by Elixhauser index (c-statistics: 0.61, Hosmer-Lemeshow: 12.1).  
In both learning and testing models, the difference in c-statistics of Elixhauser 
and COTE models was non-significant (learning, z=1.53 and testing,  
z=0.12), indicating that both measures do not differ in their discriminative 
power. CONCLUSIONS: Both, Elixhauser index and the COPD specific COTE  
index can best predict high costs in COPD patients and inclusion of either of 
them in risk adjustment models will be valuable in managing high cost COPD 
patients.  
